Journal article
Antibodies to a CA 19-9 Related Antigen Complex Identify SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and Pancreatic Adenocarcinoma
AM Farley, DR Braxton, J Li, K Trounson, S Sakar-Dey, B Nayer, T Ikeda, KX Lau, W Hardikar, K Hasegawa, MF Pera
Scientific Reports | NATURE PORTFOLIO | Published : 2019
Abstract
The Sialyl Lewis A antigen, or CA 19-9, is the prototype serum biomarker for adenocarcinoma of the pancreas. Despite extensive clinical study of CA 19-9 in gastrointestinal malignancies, surprisingly little is known concerning the specific cell types that express this marker during development, tissue regeneration and neoplasia. SOX9 is a transcription factor that plays a key role in these processes in foregut tissues. We report the biochemistry and tissue expression of the GCTM-5 antigen, a pancreatic cancer marker related to, but distinct from, CA19-9. This antigen, defined by two monoclonal antibodies recognising separate epitopes on a large glycoconjugate protein complex, is co-expressed..
View full abstractGrants
Awarded by Gastroenterological Society of Australia
Funding Acknowledgements
This study was supported by Australia India Strategic Research Fund Project BF060012; Gastroenterological Society of Australia, Indo-Australia Biotechnology Fund, DBT, India; JSPS Kakenhi 25640077 and 15K12506, Japan; Takeda Science Foundation, Japan.